Evaluation of Drug-Induced QT Interval Prolongation
暂无分享,去创建一个
[1] G Duker,et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? , 1997, The Journal of pharmacology and experimental therapeutics.
[2] L. Dubuske. Second-generation antihistamines: the risk of ventricular arrhythmias. , 1999, Clinical therapeutics.
[3] L. Dreifus,et al. Cocaine abuse: repolarization abnormalities and ventricular arrhythmias. , 2000, The American journal of the medical sciences.
[4] E SIMONSON,et al. The normal Q-T interval. , 1962, American heart journal.
[5] J. Round,et al. Muscle fibre type and aetiology of obesity , 1990, The Lancet.
[6] J. Sarma,et al. Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: significance for the control of sudden cardiac death. , 1994, American heart journal.
[7] J. Karjalainen,et al. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. , 1994, Journal of the American College of Cardiology.
[8] C Antzelevitch,et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.
[9] S. Priori,et al. Evidence for a Cardiac Ion Channel Mutation Underlying Drug‐Induced QT Prolongation and Life‐Threatening Arrhythmias , 2000, Journal of cardiovascular electrophysiology.
[10] A. Camm,et al. Circadian variation of the QT interval in patients with sudden cardiac death after myocardial infarction. , 1998, The American journal of cardiology.
[11] N. Tatsumi,et al. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide , 2000, The Lancet.
[12] A. Bénardeau,et al. Effects of the T-type Ca(2+) channel blocker mibefradil on repolarization of guinea pig, rabbit, dog, monkey, and human cardiac tissue. , 2000, The Journal of pharmacology and experimental therapeutics.
[13] S. Hohnloser,et al. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: results of a prospective, long-term follow-up study. , 1998, Circulation.
[14] I. Takei,et al. Prolonged QT interval in alcoholic autonomic nervous dysfunction. , 1992, Alcoholism, clinical and experimental research.
[15] M. Morad,et al. Suppression of mammalian K+ channel family by ebastine. , 1997, The Journal of pharmacology and experimental therapeutics.
[16] A. Brown,et al. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. , 1996, Circulation.
[17] A J Camm,et al. Short‐and Long‐Term Reproducibility of QT, QTc, and QT Dispersion Measurement in Healthy Subjects , 1994, Pacing and clinical electrophysiology : PACE.
[18] C. January,et al. Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and Norastemizole , 1999, Journal of cardiovascular electrophysiology.
[19] D. Wortham,et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.
[20] D. Wortham,et al. Itraconazole Affects Single‐Dose Terfenadine Pharmacokinetics and Cardiac Repolarization Pharmacodynamics , 1993, Journal of clinical pharmacology.
[21] P. Rautaharju,et al. Estimation of QT prolongation. A persistent, avoidable error in computer electrocardiography. , 1990, Journal of electrocardiology.
[22] B. Chaitman,et al. QT interval measurement by a computer assisted program: a potentially useful clinical parameter. , 1982, Journal of electrocardiology.
[23] M. Malik,et al. If Dr. Bazett Had Had a Computer… , 1996, Pacing and clinical electrophysiology : PACE.
[24] T. Akhtar,et al. Sudden deaths while on halofantrine treatments--a report of two cases from peshawar. , 1994, JPMA. The Journal of the Pakistan Medical Association.
[25] A. Cohen,et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers , 1998, Clinical pharmacology and therapeutics.
[26] M. Malik,et al. T-wave morphology differences between patients with and without arrhythmic complication of ischemic heart disease. , 2001, Journal of electrocardiology.
[27] R. Woosley,et al. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. , 1998, Journal of women's health.
[28] M van Bilsen,et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. , 1998, Circulation.
[29] S Nattel,et al. Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. , 1998, Circulation research.
[30] J. Cummings,et al. Quinidine Syncope: Paroxysmal Ventricular Fibrillation Occurring during Treatment of Chronic Atrial Arrhythmias , 1964, Circulation.
[31] N. Dreyer,et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. , 1999, The American journal of medicine.
[32] M. Veldkamp. Is the slowly activating component of the delayed rectifier current, IKs' absent from undiseased human ventricular myocardium? , 1998, Cardiovascular research.
[33] Interobserver Reproducibility of QT Interval Measurement and QT Dispersion in Patients After Acute Myocardial Infarction , 1996 .
[34] Electrophysiological effects of LU111995 on canine hearts: in vivo and in vitro studies. , 1999, The Journal of pharmacology and experimental therapeutics.
[35] H. Friedman,et al. The effects of erythromycin on the electrocardiogram. , 1999, Chest.
[36] Fesc,et al. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. , 1997, Journal of the American College of Cardiology.
[37] D. Jorkasky,et al. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. , 1997, Journal of clinical psychopharmacology.
[38] J. Barhanin,et al. Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. , 2000, Therapie.
[39] A Pagliara,et al. Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist. , 1998, Journal of medicinal chemistry.
[40] D J Triggle,et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.
[41] A. Brown,et al. Cardiovascular safety of fexofenadine HCl , 1999, Clinical and Experimental Allergy.
[42] C. Lau,et al. Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate. , 1988, Cardiovascular research.
[43] J. Camm,et al. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. , 1998, European heart journal.
[44] S. Swiryn,et al. Torsade de pointes due to quinidine: observations in 31 patients. , 1984, American heart journal.
[45] Y Watanabe,et al. Purkinje repolarization as a possible cause of the U wave in the electrocardiogram. , 1975, Circulation.
[46] J. Brachmann,et al. Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study , 1998, Pacing and clinical electrophysiology : PACE.
[47] M. Viitasalo,et al. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome , 1994, Clinical cardiology.
[48] R S Reneman,et al. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. , 1989, Journal of pharmacological methods.
[49] N. Dascal,et al. The use of Xenopus oocytes for the study of ion channels. , 1987, CRC critical reviews in biochemistry.
[50] J Weissenburger,et al. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. , 1995, Journal of the American College of Cardiology.
[51] B. Surawicz,et al. Will QT Dispersion Play a Role in Clinical Decision‐Making? , 1996, Journal of cardiovascular electrophysiology.
[52] Y. Rudy,et al. Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia , 1999, Nature.
[53] Diederick E Grobbee,et al. T axis as an indicator of risk of cardiac events in elderly people , 1998, The Lancet.
[54] M Malik,et al. Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion. , 1998, The American journal of cardiology.
[55] C. Zywietz,et al. Analysis of interval measurements on CSE multilead reference ECGs. , 1996, Journal of electrocardiology.
[56] B Attali,et al. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes , 1997, British journal of pharmacology.
[57] M. Bras,et al. Prolonged QT interval with halofantrine , 1993, The Lancet.
[58] A. Roach,et al. Preclinical In Vitro Cardiac Electrophysiology , 1999, Drug safety.
[59] C. Antzelevitch,et al. Effects of Sodium Channel Block with Mexiletine to Reverse Action Potential Prolongation in In Vitro Models of the Long QT Syndrome , 1997, Journal of cardiovascular electrophysiology.
[60] D. Beuckelmann,et al. Characterization of the hyperpolarization-activated inward current in isolated human atrial myocytes. , 1998, Cardiovascular research.
[61] P W Macfarlane,et al. Influence of lead selection and population on automated measurement of QT dispersion. , 1998, Circulation.
[62] W. Rafflenbeul,et al. QT prolongation due to roxithromycin , 2000, Postgraduate medical journal.
[63] W Adams,et al. THE NORMAL DURATION OF THE ELECTROCARDIOGRAPHIC VENTRICULAR COMPLEX. , 1936, The Journal of clinical investigation.
[64] M. Malik,et al. Comparison of Different Methods for Manual P Wave Duration Measurement in 12‐Lead Electrocardiograms , 1999, Pacing and clinical electrophysiology : PACE.
[65] Benjamin A Lipsky,et al. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic. , 1999, Clinical therapeutics.
[66] A. Brown,et al. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG , 1997, FEBS letters.
[67] P. Pollak. Oral Amiodarone: Historical Overview and Development , 1998, Pharmacotherapy.
[68] B. Surawicz. Long QT: good, bad, indifferent and fascinating , 1999 .
[69] M Kawataki,et al. Relation between QT interval and heart rate. applications and limitations of Bazett's formula. , 1984, Journal of electrocardiology.
[70] B. Surawicz,et al. Ventricular arrhythmias: why is it so difficult to find a pharmacologic cure? , 1989, Journal of the American College of Cardiology.
[71] C. Naspitz,et al. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[72] J. Brugada,et al. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. , 1992, Journal of the American College of Cardiology.
[73] K. Woods,et al. Reproducibility and automatic measurement of QT dispersion. , 1996, European heart journal.
[74] R. Lazzara. Antiarrhythmic drugs and torsade de pointes. , 1993, European heart journal.
[75] M. Malik,et al. Measurement, interpretation and clinical potential of QT dispersion. , 2000, Journal of the American College of Cardiology.
[76] M Malik,et al. Analysis of 12-Lead T-Wave Morphology for Risk Stratification After Myocardial Infarction , 2000, Circulation.
[77] J. Sarma,et al. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: reevaluation of Bazett's formula. , 1984, The American journal of cardiology.
[78] E. Carmeliet,et al. Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine , 1998, British Journal of Pharmacology.
[79] D. Roden,et al. Abnormalities of the QT interval in primary disorders of autonomic failure. , 1998, American heart journal.
[80] Robert C. Schlant,et al. Advances in electrocardiography , 1976 .
[81] S. Nattel,et al. Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes. , 2000, Cardiovascular research.
[82] M Malik,et al. Problems of Heart Rate Correction in Assessment of Drug‐Induced QT Interval Prolongation , 2001, Journal of cardiovascular electrophysiology.
[83] CHARLES ANTZELEVITCH,et al. The M Cell: , 1999, Journal of cardiovascular electrophysiology.
[84] L. Dubé,et al. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine , 1997, European Journal of Clinical Pharmacology.
[85] G. Kay,et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. , 1983, Journal of the American College of Cardiology.
[86] P E Tikkanen,et al. Using simulated noise to define optimal QT intervals for computer analysis of ambulatory ECG. , 1999, Medical engineering & physics.
[87] M. Hodges. Bazett's QT correction reviewed : Evidence that a linear QT correction for heart rate is better , 1983 .
[88] T J Campbell,et al. Inhibition of HERG potassium channels by the antimalarial agent halofantrine , 2000, British journal of pharmacology.
[89] K. Eguchi,et al. Clarithromycin associated with torsades de pointes. , 1999, Japanese circulation journal.
[90] J. Vandenbroucke,et al. QT Interval Prolongation Predicts Cardiovascular Mortality in an Apparently Healthy Population , 1991, Circulation.
[91] Walter Stühmer,et al. Electrophysiological recording from Xenopus oocytes. , 1992, Methods in enzymology.
[92] H. Bazett,et al. AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .
[93] I. Gathmann,et al. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[94] A. Boobis,et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice , 1997, European Journal of Clinical Pharmacology.
[95] H. Wellens,et al. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium. , 1997, Cardiovascular research.
[96] M. Malik,et al. Human Precision of Operating a Digitizing Board: Implications for Electrocardiogram Measurements , 1998, Pacing and clinical electrophysiology : PACE.
[97] E. Kaplinsky,et al. Q-T prolongation and polymorphous ("torsade de pointes") ventricular arrhythmias associated with organophosphorus insecticide poisoning. , 1982, The American journal of cardiology.
[98] S. Olson,et al. Atorvastatin does not Produce a Clinically Significant Effect on the Pharmacokinetics of Terfenadine , 1998, Journal of clinical pharmacology.
[99] Wojciech Zareba,et al. Spectrum of ST-T–Wave Patterns and Repolarization Parameters in Congenital Long-QT Syndrome: ECG Findings Identify Genotypes , 2000, Circulation.
[100] H. Crijns,et al. QT lengthening and life-threatening arrhythmias associated with fexofenadine , 1999, The Lancet.
[101] G. Oster,et al. Use of terfenadine and contraindicated drugs. , 1996, JAMA.
[102] D. Wortham,et al. Comparison of the Effect of the Macrolide Antibiotics Erythromycin, Clarithromycin and Azithromycin on Terfenadine Steady-State Pharmacokinetics and Electrocardiographic Parameters , 1994 .
[103] D. Levy,et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) , 1992, The American journal of cardiology.
[104] H. Wellens,et al. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. , 1995, Circulation.
[105] B. Surawicz,et al. The Measurement of the Q‐T Interval of the Electrocardiogram , 1952, Circulation.
[106] D. Wortham,et al. Grapefruit Juice Alters the Systemic Bioavailability and Cardiac Repolarization of Terfenadine in Poor Metabolizers of Terfenadine , 1996, Journal of clinical pharmacology.
[107] Pentti M. Rautaharju,et al. QT and Dispersion of Ventricular Repolarization: The Greatest Fallacy in Electrocardiography in the 1990s , 1999 .
[108] R. Woosley,et al. Pharmacies and prevention of potentially fatal drug interactions. , 1996, JAMA.
[109] M. Boiocchi,et al. Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit. , 1999, Critical care medicine.
[110] P Rubel,et al. Are serial Holter QT, late potential, and wavelet measurement clinically useful? , 1996, Journal of Electrocardiology.
[111] M. Eller,et al. Azithromycin and terfenadine: Lack of drug interaction , 1995, Clinical pharmacology and therapeutics.
[112] Morrison Hodges,et al. Rate Correction of the QT Interval , 1997 .
[113] J. Mccomb,et al. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. , 1990, British heart journal.
[114] P. Coumel,et al. Diagnostic performance of QT interval variables from 24-h electrocardiography in the long QT syndrome. , 1998, European heart journal.
[115] R. Woosley,et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.
[116] J A Kors,et al. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. , 1999, European heart journal.
[117] R. Ashman,et al. The normal duration of the Q-T interval , 1942 .
[118] D. Roden,et al. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.
[119] B. Sakmann,et al. Single-Channel Recording , 1995, Springer US.
[120] J. Weiss,et al. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. , 1996, Journal of the American College of Cardiology.
[121] A J Camm,et al. Computerised measurements of QT dispersion in healthy subjects , 1998, Heart.
[122] P Rubel,et al. An improved method for the precise measurement of serial ECG changes in QRS duration and QT interval. Performance assessment on the CSE noise-testing database and a healthy 720 case-set population. , 1992, Journal of electrocardiology.
[123] P. Sanders,et al. Cardiovascular Adverse Effects of Antipsychotic Drugs , 2000, Drug safety.
[124] D. Flockhart,et al. Greater quinidine‐induced QTc interval prolongation in women , 2000, Clinical pharmacology and therapeutics.
[125] D. Roden,et al. From genes to channels: normal mechanisms. , 1999, Cardiovascular research.
[126] S. Hohnloser. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. , 1997, The American journal of cardiology.
[127] R. Woosley,et al. Mechanism of cardiotoxicity of halofantrine , 2000, Clinical pharmacology and therapeutics.
[128] A J Camm,et al. QT Interval and QT Dispersion Measured with the Threshold Method Depend on Threshold Level , 1998, Pacing and clinical electrophysiology : PACE.
[129] J. Davy,et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. , 1991, The Journal of pharmacology and experimental therapeutics.
[130] P. Neuvonen,et al. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride , 1999, Clinical pharmacology and therapeutics.
[131] R. Ruffolo,et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. , 1996, The Journal of pharmacology and experimental therapeutics.
[132] T. Hoon. Performance of an Electrocardiographic Analysis System: Implications for Pharmacodynamic Studies , 1996, Pharmacotherapy.
[133] B. Ring,et al. Effect of Dirithromycin on Human CYP3A In Vitro and on Pharmacokinetics and Pharmacodynamics of Terfenadine In Vivo , 1996, Journal of clinical pharmacology.
[134] Senén Barro,et al. A new approach for TU complex characterization , 2000, IEEE Transactions on Biomedical Engineering.
[135] C Antzelevitch,et al. Role of M cells in acquired long QT syndrome, U waves, and torsade de pointes. , 1995, Journal of electrocardiology.
[136] R. Benton,et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram , 1996, Clinical pharmacology and therapeutics.
[137] D M Roden,et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[138] D. Roden,et al. Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. , 1996, The American journal of cardiology.
[139] G. Breithardt,et al. Experimental models of torsade de pointes. , 1998, Cardiovascular research.
[140] P Caminal,et al. Automatic detection of wave boundaries in multilead ECG signals: validation with the CSE database. , 1994, Computers and biomedical research, an international journal.
[141] C Antzelevitch,et al. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. , 1998, Circulation.
[142] D. Flockhart,et al. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. , 1998, Journal of clinical psychopharmacology.
[143] L. Fauchier,et al. Effect of verapamil on QT interval dynamicity. , 1999, The American journal of cardiology.
[144] M. Malik,et al. “Optimum” Formulae for Heart Rate Correction of the QT Interval , 1999, Pacing and clinical electrophysiology : PACE.
[145] M. Lehmann,et al. Sex difference in risk of torsade de pointes with d,l-sotalol. , 1996, Circulation.
[146] B. Surawicz. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations? , 1989, Journal of the American College of Cardiology.
[147] K. Hussain,et al. A Review of Erythromycin-Induced Malignant Tachyarrhythmia— Torsade de Pointes , 1997, Angiology.
[148] M Restivo,et al. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. , 1996, Circulation research.
[149] R. Perera,et al. Prolonged QT interval and cocaine use. , 1997, Journal of electrocardiology.
[150] D L Kunze,et al. Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event. , 1993, The American journal of cardiology.
[151] A. Templeton,et al. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. , 2000, European journal of pharmacology.
[152] J. Fothergill,et al. Automated measurement of QT interval dispersion from hard-copy ECGs. , 1993, Journal of electrocardiology.
[153] T. Koide,et al. Etiology of QT prolongation and T wave changes in chronic alcoholism. , 1981, Japanese heart journal.
[154] G. Gross,et al. Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists. , 2000, Canadian journal of physiology and pharmacology.
[155] Bramahn . Singh,et al. Effects of Sotalol on the Circadian Rhythmicity of Heart Rate and QT Intervals With a Noninvasive Index of Reverse-Use Dependency , 1999, Journal of cardiovascular pharmacology and therapeutics.
[156] Q Xue,et al. Algorithms for computerized QT analysis. , 1998, Journal of electrocardiology.